Erectile Dysfunction Options

dreamstime_m_17908700.jpg

Good news! Viagra is now generic.

The price has dropped from $70 a pill to only $30 a tablet!! If that is still to pricey for you, you should take a look at this low cost saving substitution.

Revatio is a drug with the same active ingredient as Viagra, it is just used to treat a condition called pulmonary hypertension. Revatio's active ingredient is sildenafil citrate , the same as Viagra. It is dosed at a smaller strength of 20mg. Revatio is available as a generic for $2 a tablet. By taking one to five tablets you can get similar results to treat Erectile Dysfunction as you get by taking the 25mg,50mg, or 100mg Viagra.

Generic Viagra (Sildenafil) 50mg & 100mg

The 50mg and 100mg sildenafil tablets are now generic, however the price has not come down much from the brand name pricing of Viagra. These tablets are still more than $30 per pill! If you treat the same condition with Revatio tablets your maximum out of pocket cost would be $10.

We cannot substitute Revatio for Viagra , your doctor must write for Revatio 20mg or Sildenafil 20mg .

Sildenafil 20mg #30 Take 1-5 tablets 1 hour prior to intercourse.

Call us today at 214-473-8682 and speak with our pharmacy staff to get your prescription transferred to Willow Bend Pharmacy today! We also will reach out to your physician's office for a refill request. Mailing is offered in the state of Texas.

Remember that Revatio is essentially the same drug as Viagra. It causes the same side effects like head ache, stuffy nose, blue vision, erections that wont go away and may need medical attention . You cannot take Revatio if you are on nitroglycerin.

Maximum dosage: 100 mg once per day (Viagra); 20 mg 3 times daily (Revatio) according to the prescribing information.

Onset: Erectile dysfunction: ~60 minutes; Peak effect: Decrease blood pressure: Oral: 1 to 2 hours

Duration: Erectile dysfunction: 2 to 4 hours; Decrease blood pressure: <8 hours

Warnings & Precautions

  • Cardiovascular disease: Use with caution in patients with hypotension (less than 90/50 mm Hg); uncontrolled hypertension (greater than 170/110 mm Hg); life-threatening arrhythmias, stroke, or myocardial infarction within the last 6 months; cardiac failure or coronary artery disease causing unstable angina; safety and efficacy have not been studied in these patients. Use caution in patients with left ventricular outflow obstruction (eg, aortic stenosis). There is a degree of cardiac risk associated with sexual activity; therefore, health care providers should consider the cardiovascular status of their patients prior to initiating any treatment for erectile dysfunction.
  • Priapism: Painful erection longer than 6 hours in duration has been reported rarely. Alert patients to seek medical assistance for erection lasting longer than 4 hours.
  • Conditions predisposing to priapism: Use with caution in patients who have conditions that may predispose them to priapism (sickle cell anemia, multiple myeloma, leukemia). Instruct all patients to seek immediate medical attention if erection persists longer than 4 hours.
  • Anatomical penis deformation: Use with caution in patients with anatomical deformation of the penis (angulation, cavernosal fibrosis, or Peyronie disease).
  • Appropriate use: Evaluate potential underlying causes of ED prior to treatment.
  • Hypotension: Decreases in blood pressure may occur due to vasodilator effects; use with caution in patients with left ventricular outflow obstruction (aortic stenosis, hypertrophic obstructive cardiomyopathy), those on antihypertensive therapy, with resting hypotension (blood pressure less than 90/50 mm Hg), fluid depletion, or autonomic dysfunction; may be more sensitive to hypotensive actions. Patients should be hemodynamically stable prior to initiating therapy at the lowest possible dose. Monitor blood pressure when combining with medications that lower blood pressure.
  • Pulmonary arterial hypertension: Sudden cessation of sildenafil monotherapy could result in an exacerbation of PAH. Efficacy in adults determined through short-term (12 to 16 week) studies; safety of longer-term use is unclear. A long-term use trial in pediatric patients showed increased mortality in the higher dose groups (20 to 80 mg [depending upon weight] 3 times/day) after 2 years of use.
  • Sickle cell anemia: Treatment of pulmonary hypertension with sildenafil in this patient population may lead to more hospitalizations for management of vaso-occlusive crises. The effectiveness and safety of sildenafil have not been established in pulmonary hypertension secondary to sickle cell disease.
  • Pulmonary edema: If pulmonary edema occurs when treating PAH, consider the possibility of pulmonary veno-occlusive disease (PVOD); continued use is not recommended in patients with PVOD.
  • Bleeding disorders: Use with caution in patients with bleeding disorders; safety has not been established. In vitro studies have suggested a decreased effect on platelet aggregation.
  • Vision loss: Sudden loss of vision in one or both eyes, including permanent loss of vision, may occur and be a sign of nonarteritic anterior ischemic optic neuropathy (NAION). Risk may be increased with history of vision loss. Other risk factors for NAION include low cup-to-disc ratio ("crowded disc"), coronary artery disease, diabetes, hypertension, hyperlipidemia, smoking, and >50 years of age. A direct relationship between therapy and vision loss has not been determined.
  • Color discrimination: May cause dose-related impairment of color discrimination. Use caution in patients with retinitis pigmentosa; a minority have genetic disorders of retinal phosphodiesterases (no safety information available).
  • Hearing loss: Sudden decrease or loss of hearing has been reported; hearing changes may be accompanied by tinnitus and dizziness. A direct relationship between therapy and hearing loss has not been determined.
  • Peptic ulcer disease: Use with caution in patients with active peptic ulcer disease; safety has not been established.
  • Oral suspension: Oral suspensions may be available in multiple concentrations (extemporaneous preparation: 2.5 mg/mL; commercially available: 10 mg/mL); dosing should be presented in mg of sildenafil; use extra precautions when verifying product formulation and calculation of dose volumes. The oral syringe provided by the manufacturer only provides measurements for fixed doses of 5 mg or 20 mg; for patients not receiving either of these fixed doses, a 1 mL oral syringe will need to be dispensed.
  • Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid. Benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (99 mg/kg/day or more) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse. Some data suggest that benzoate displaces bilirubin from protein-binding sites; avoid or use dosage forms containing benzyl alcohol derivatives with caution in neonates

p: 214-473-8682

f: 214-291-0816